Patient considerations in the management of ulcerative colitis: role of once-daily MMX mesalamine

References

• EadenJAAbramsKRMayberryJFThe risk of colorectal cancer in ulcerative colitis: a meta-analysisGut200148452653511247898
   PubMed Web of Science ®Google Scholar
• CasellasFLópez-VivancosJBadiaXVilasecaJMalageladaJRInfluence of inflammatory bowel disease on different dimensions of quality of lifeEur J Gastroenterol Hepatol200113556757211396538
   PubMed Web of Science ®Google Scholar
• CasellasFArenasJIBaudetJSImpairment of health-related quality of life in patients with inflammatory bowel disease: a Spanish multicenter studyInflamm Bowel Dis200511548849615867589
   PubMed Web of Science ®Google Scholar
• JankeKHKlumpBGregorMMeisnerCHaeuserWDeterminants of life satisfaction in inflammatory bowel diseaseInflamm Bowel Dis200511327228615735434
   PubMed Web of Science ®Google Scholar
• NielsenOHMunckLKDrug insight: aminosalicylates for the treatment of IBDNat Clin Pract Gastroenterol Hepatol20074316017017339853
   PubMedGoogle Scholar
• HuMYPeppercornMAMMX mesalamine: a novel high-dose, once-daily 5-aminosalicylate formulation for the treatment of ulcerative colitisExpert Opin Pharmacother2008961049105818377346
   PubMed Web of Science ®Google Scholar
• KaneSHuoDAikensJHanauerSMedication nonadherence and the outcomes of patients with quiescent ulcerative colitisAm J Med20031141394312543288
   PubMed Web of Science ®Google Scholar
• KaneSVCohenRDAikensJEHanauerSBPrevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitisAm J Gastroenterol200196102929293311693328
   PubMed Web of Science ®Google Scholar
• LichtensteinGRKammMABodduPEffect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitisClin Gastroenterol Hepatol2007519510217234558
   PubMed Web of Science ®Google Scholar
• KammMASandbornWJGassullMOnce-daily high concentration MMX mesalamine in active ulcerative colitisGastroenterology20071321667517241860
   PubMed Web of Science ®Google Scholar
• SandbornWJKammMALichtensteinGRLyneAButlerTJosephREMulti Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trialsAliment Pharmacol Ther200726220521517593066
   PubMed Web of Science ®Google Scholar
• KammMALichtensteinGRSandbornWJRandomized trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitisGut200857789390218272546
   PubMed Web of Science ®Google Scholar
• KaiserGCYanFPolkDBMesalamine blocks tumor necrosis factor growth inhibition and nuclear factor kappaB activation in mouse colonocytesGastroenterology1999116360260910029619
   PubMed Web of Science ®Google Scholar
• BakerDEMMX MesalamineRev Gastroenterol Disord20066414615216957657
   PubMedGoogle Scholar
• BrunnerMAssandriRKletterKGastrointestinal transit and 5-ASA release from a new mesalazine extended-release formulationAliment Pharmacol Ther200317339540212562452
   PubMed Web of Science ®Google Scholar
• PranteraCViscidoABianconeLFrancavillaAGiglioLCampieriMA new oral delivery system for 5-ASA: preliminary clinical findings for MMxInflamm Bowel Dis200511542142715867580
   PubMed Web of Science ®Google Scholar
• HussainFNAjjanRAKapurKMoustafaMRileySAOnce versus divided daily dosing with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parametersAliment Pharmacol Ther2001151536211136278
   PubMed Web of Science ®Google Scholar
• CoreyAERoseGMConklinJDBioavailability of single and multiple doses of enteric-coated mesalamine and sulphasalazineJ Int Med Res19901864414531981363
   PubMed Web of Science ®Google Scholar
• SandbornWJHanauerSBSystematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitisAliment Pharmacol Ther2003171294212492730
   PubMed Web of Science ®Google Scholar
• IrelandAPriddleJDJewellDPAcetylation of 5-aminosalicylic acid by isolated human colonic epithelial cellsClin Sci (Lond)19907811051112153487
   PubMed Web of Science ®Google Scholar
• KlotzUClinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acidClin Pharmacokinet19851042853022864155
   PubMed Web of Science ®Google Scholar
• HanauerSBSandbornWJKornbluthADelayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trialAm J Gastroenterol2005100112478248516279903
   PubMed Web of Science ®Google Scholar
• HanauerSBSandbornWJDallaireCDelayed-release oral mesa-lamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trialCan J Gastroenterol2007211282783418080055
   PubMed Web of Science ®Google Scholar
• KammMALichtensteinGRSandbornWJEffect of extended MMX mesalamine therapy for acute, mild-to-moderate Ulcerative ColitisInflamm Bowel Dis20091511818671232
   PubMed Web of Science ®Google Scholar
• LoftusEVJrKaneSVBjorkmanDSystematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitisAliment Pharmacol Ther200419217918914723609
   PubMed Web of Science ®Google Scholar
• MinerPHanauerSRobinsonMSchwartzJAroraSSafety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study GroupDig Dis Sci19954022963047851193
   PubMed Web of Science ®Google Scholar
• SutherlandLMacdonaldJKOral 5-aminosalicylic acid for maintenance of remission in ulcerative colitisCochrane Database Syst Rev2006192CD00054416625537
   PubMedGoogle Scholar
• DasKMEastwoodMAMcManusJPSircusWAdverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotypeN Eng J Med197328910491495
   PubMed Web of Science ®Google Scholar
• CohenRDWosethDMThistedRAHanauerSBA meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitisAm J Gastroenterol2000955126376LoftusEVA practical perspective on ulcerative colitis: patients’ needs from aminosalicylate therapiesInflamm Bowel Dis2006121211071113
   PubMed Web of Science ®Google Scholar
• D’HaensGHommesDEngelsJOnce daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging studyAliment Pharmacol Ther20062471087109716984503
   PubMed Web of Science ®Google Scholar
• HandeSWilson-RichNBousvarosA5-aminosalicylate therapy is associated with higher 6-thioguanine levels in adults and children with inflammatory bowel disease in remission on 6-mercaptopurine or azathioprineInflamm Bowel Dis200612425125716633046
   PubMed Web of Science ®Google Scholar
• DewitOVanheuverzwynRDesagerJPHorsmansYInteraction between azathioprine and aminosalicylates: an in vivo study in patients with Crohn’s diseaseAliment Pharmacol Ther2002161798511856081
   PubMed Web of Science ®Google Scholar
• LoftusEVA practical perspective on ulcerative colitis: patients’ needs from aminosalicylate therapiesInflamm Bowel Dis200612121107111317119384
   PubMed Web of Science ®Google Scholar
• ShaleMJRileySAStudies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel diseaseAliment Pharmacol Ther200318219119812869079
   PubMed Web of Science ®Google Scholar
• LevyRLFeldADIncreasing patient adherence to gastroenterology treatment and prevention regimensAm J Gastroenterol19999471733174210406229
   PubMed Web of Science ®Google Scholar
• KaneSHuoDMagnantiKA pilot feasibility study of once daily dosing versus conventional dosing mesalamine for maintenance of ulcerative colitisClin Gastroenterol Hepatol20031317017315017487
   PubMed Web of Science ®Google Scholar
• KediaPCohenRDOnce-daily MMX mesalamine for the treatment of mild-to-moderate ulcerative colitisTher Clin Risk Manag20073591992718473016
   PubMedGoogle Scholar